Triple negative breast cancer in the era of miRNA

Hussein Sabit; Emre Cevik; Huseyin Tombuloglu; Shaimaa Abdel-Ghany; Guzin Tombuloglu; Manel Esteller

doi:10.1016/j.critrevonc.2020.103196

Triple negative breast cancer in the era of miRNA

Crit Rev Oncol Hematol. 2021 Jan:157:103196. doi: 10.1016/j.critrevonc.2020.103196. Epub 2020 Dec 9.

Authors

Hussein Sabit¹, Emre Cevik², Huseyin Tombuloglu², Shaimaa Abdel-Ghany³, Guzin Tombuloglu⁴, Manel Esteller⁵

Affiliations

¹ Department of Genetics, Institute for Medical Research and Consultations, Imam Abdulrahman Bin Faisal University, P. O. Box: 1982, 31441, Dammam, Saudi Arabia. Electronic address: hhsabit@iau.edu.sa.
² Department of Genetics, Institute for Medical Research and Consultations, Imam Abdulrahman Bin Faisal University, P. O. Box: 1982, 31441, Dammam, Saudi Arabia.
³ Department of Environmental Biotechnology, College of Biotechnology, Misr University for Science and Technology, P. O. Box 77, Giza, Egypt.
⁴ AdnanKahveci Mah, Mimar Sinan Cad., Mavisu Evl, 7/28 Beylikduzu, Istanbul, Turkey.
⁵ Josep Carreras Leukemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), 28029, Madrid, Spain; Institucio Catalana de Recerca i Estudis Avançats(ICREA), Barcelona, Catalonia, Spain; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Catalonia, Spain.

PMID: 33307198
DOI: 10.1016/j.critrevonc.2020.103196

Abstract

The objective of this review is to elucidate the role of miRNAs in triple negative breast cancer (TNBC). To achieve our goal, we searched databases such as PubMed, ScienceDirect, Springer, Web of Science and Scopus. We retrieved up to 1233 articles, based a rigorous selection criterion, only 197 articles were extensively reviewed. We selected articles only addressing TNBC, but not other types of breast cancer, with the employed approach being miRNA analysis and/or profiling. Our extensive review resulted in grouping of miRNAs into categories in which specific members of miRNAs have roles in specific mechanism in TNBC i.e., carcinogenesis, invasion, metastasis, apoptosis, diagnosis, prognosis, and treatment. TNBC is an aggressive subtype of breast cancer; therefore, different approaches for accurate diagnosis, prognosis and treatment are needed. In this review we summarize the up-to-date miRNA profiling, prognostic, and therapeutic findings that add to the route of controlling TNBC.

Keywords: Epigenomics; Metastasis; MicroRNAs; Neoplasm; Triple negative breast cancer.

Publication types

Review

MeSH terms

Apoptosis
Biomarkers, Tumor / genetics
Carcinogenesis
Gene Expression Regulation, Neoplastic
Humans
MicroRNAs* / genetics
Prognosis
Triple Negative Breast Neoplasms* / diagnosis
Triple Negative Breast Neoplasms* / genetics

Substances

Biomarkers, Tumor
MicroRNAs